Arcturus Narrows Q3 Loss to $7.4 Million
The clinical-stage biotech reported revenue growth driven by a one-time termination payment tied to the end of its CSL Seqirus collaboration.
Updated on Nov. 7, 2026 in Biotech
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) reported a third-quarter net loss of $7.4 million for the quarter ended September 30, 2026, down from $13.4 million a year earlier. Revenue rose 6.7% to $18.3 million.
Why it matters
The narrower loss and revenue increase reflect one-time accounting effects rather than purely recurring operating growth. Investors and partners watch quarterly figures like these to gauge how the company's collaboration income holds up once special payments roll off.
Collaboration revenue rose to $16.9 million from $14.2 million, while grant revenue fell to $1.4 million from $3 million. The company's GAAP loss per share was $0.26 for the quarter.
The players
Arcturus Therapeutics Holdings Inc.
A clinical-stage biopharmaceutical company trading on Nasdaq under the ticker ARCT, focused on messenger RNA-based therapeutics.
CSL Seqirus
The influenza vaccine business of Australian biotechnology company CSL, whose collaboration with Arcturus ended and triggered the termination payment.
The details
Revenue growth primarily reflected a $12 million termination payment and recognition of remaining deferred revenue after the CSL Seqirus collaboration ended. Lower grant revenue partly offset the gains from collaboration income.
Timeline
September 30, 2026: Quarter ended, with a net loss of $7.4 million.
November 7, 2026: Third-quarter results published.
Big Picture
The quarter's results are shaped by the wind-down of the CSL Seqirus collaboration, which produced a one-time $12 million termination payment. Arcturus's reported revenue growth therefore depends heavily on partnership milestones rather than steady product sales.
For patients and investors, the quarter's figures signal how much Arcturus relies on partner payments to fund its work. Readers tracking mRNA therapies can use these results to compare the company's progress against peers.
The takeaway
Revenue spikes tied to one-time payments can make quarterly results look stronger than underlying operations. Readers should check whether a company's gains come from recurring income or from a single event.
Further reading
For more on the sector, see Biotech coverage of drug developers and their partnership deals.
Source note: This article includes information reported by TokenPost.
